Our net income attributable to common shareholders for the third quarter of 2022 was $8.1 million or $0.12 per share compared to $3.7 million or $0.06 per share in the third quarter of 2021.
Including a $6.8 million gain from the sale of property, net income attributable to common stockholders for the third quarter of 2022 was $8.1 million or $0.12 per share compared to $3.7 million or $0.06 per share in the third quarter of 2021.
Additionally, behind these 2 large expirations currently, there are no individually material leases that we don't expect to renew.
FFO in the third quarter was $16.2 million or $0.23 per share and unit compared to $15.8 million or $0.23 per share and unit in the third quarter of 2021.
We achieved an 18.1% year-over-year increase in total revenue to $35.4 million driven primarily by our acquisition activity over the past year, including a $6.8 million gain from the sale of a property.
FFO in the third quarter was $0.23 per share and unit, in line with last year.
In the third quarter, we achieved an 18.1% year-over-year increase in total revenue to $35.4 million driven primarily by our acquisition activity over the past year.
And our AFFO per share increased by $0.01 to $0.25 per share and unit compared to the third quarter of 2021.
AFFO in the third quarter was $17.1 million or $0.25 per share and unit compared to $16.4 million or $0.24 per share and unit in the third quarter of 2021.
On a same-store basis, excluding cash basis leases, our third quarter revenues were up $344,000 or 1.4% compared to the third quarter of 2021.
Our high-quality portfolio of needs-based health care facilities continues to produce excellent results in the third quarter with 97% occupancy and a stable cash flow.
With nearly $150 million of acquisitions closed so far in 2022, we will remain disciplined as we look at incremental growth for the balance of 2022 and into 2023.
As we look ahead to 2023 lease expirations, note that more than half of this ABR relates to 2 single-tenant facilities that are progressing well towards renewals.
With regards to dispositions, in the third quarter, we sold our medical office building in Germantown, Tennessee, receiving gross proceeds of $17.9 million, resulting in a gain on sale of $6.8 million.
That said, in the third quarter, we continue to find attractive acquisitions that meet our quality and yield targets, closing 5 acquisitions for $51 million.
Looking ahead, we expect our Q4 G&A expenses to be between $4 million and $4.2 million.